News
Please, enter cell line, author or any other phrase or word you would like to search for.
Interim Report 3 2022/23
Sales have continued to grow, with significantly higher cost efficiency. As a result, rolling 12-month sales gained to its highest level ever.
Clarification Regarding Potential Collaborations
Thi information is provided to mitigate any misinterpretation of the information unintentionally made publicly after a PHI presentation at a CERN Knowledge Transfer Seminar held on March 27, 2023.
Notice that Interim Report 3 2022/23 will be published already on March 28, 2023
PHI changes the date for publication of Interim Report 3 2022/23 to March 28, 2023.
PHI creates a subsidiary for the anticipated EU patent concerning synthetic antibodies
PHI has decided to create a dedicated subsidiary to house the synthetic antibody patent family and facilitate its business potential.
CERN seminar: The Promise of Regenerative Medicine and AI
During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.
BioStock: PHI catches eye of major investor
BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.
Swiss-based Altium acquires major stake in PHI
PHI announces that Altium S.A. recently acquired Formue Nord’s entire holdings in PHI of 2 416 679 shares and 1 491 362 TO 3 warrants and committed to exercise the obtained warrants.
BioStock: PHI comments on the new senior positions in the company
BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.
PHI expands its global network to India
PHI has entered a business relationship with Medi Analytika India Pvt. Ltd. This new distributor will represent PHI in the large and growing Indian market and manage the full sales process and customer relations for the HoloMonitor® product portfolio.
PHI Focuses on Biomanufacturing — Appoints New CEO and Chairman
The Board of Directors of PHI has appointed the company’s CFO, Patrik Eschricht, as the new CEO. In addition, the former CEO and founder of PHI, Peter Egelberg, has been appointed executive chairman of the Board.